LAUSR

Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers (sqNSCLC). However, reuse of PD‐1/L1 inhibitor in second‐line beyond progression after the first‐line is generally not recommended. Therefore, oncologists face challenges in making a proper decision of using PD‐1/L1 inhibitor. This analysis aimed to determine whether it is more cost‐effective to use sintilimab, a domestic anti‐PD‐1 drug in China, as a first‐line treatment than reserving it until second‐line.